Autoimmune Diseases

Autoimmune and inflammatory diseases comprise a range of disorders that are connected by the fact that white blood cells in these patients are chronically activated at high levels. Specifically, LFA-1, the target for Leukothera™ is very highly expressed in an active state on these white blood cells. Thus, diseased white blood cells in patients with autoimmune diseases are preferential targets for Leukothera™.

Several key facts about Leukothera™ for treatment of autoimmune and inflammatory disorders:

  • LFA-1, the receptor for Leukothera™, is highly expressed on white blood cells in patients with these diseases.
  • Leukothera™ is highly effective at resolving psoriasis in a humanized animal model.
  • LFA-1 has been validated in experimental animals and humans to be a valid target for treating autoimmune diseases.

Hematologic Diseases

Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera™ is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals.

Read More

Autoimmune Diseases

Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues.

Read More

HIV

HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.

Read More